Download in electronic PDF format for $25

Search the Complete Journal Archives

Nifedpine in Compounded Oral and Topical Preparations

Author(s):  McCluskey Susan V, Brunn Gregory J

Issue:  Mar/Apr 2011 - Volume 15, Number 2
View All Articles in Issue

Abstract:  The purpose of this study was to evaluate nifedipine oral and topical compounding formulas and procedures. Topical preparations were compounded in Plastibase 50 W, using combinations of two drug sources and four types of light exposure. Oral preparations were compounded using combinations of two drug sources, two types of light exposure, and four suspending vehicles. Drug sources consisted of the contents of commercial nifedipine soft-gelatin capsules and nifedipine powder USP. Light exposures were ambient, red-shaded, goldshaded fluorescent light, or a combination of ambient and gold-shaded fluorescent light. Topical formulations were assessed for potency, uniformity, and usability characteristics such as acceptable look and feel of the preparation. Oral formulations were assessed for potency, uniformity, and usability characteristics, such as acceptable look and taste of the preparation. Preparations which were compounded, in entirety, under gold-shaded fluorescent light with nifedipine powder USP as the drug source resulted in a potency of 90% to 110% of intended value. Preparations that were exposed to ambient or red-shaded fluorescent light at any time in the compounding procedure resulted in subpotent preparations. Nifedipine is sensitive to certain wavelengths of light resulting in rapid degradation. When exposed to fluorescent room light, significant degradation may occur in a time frame less than what may be required to compound a preparation, necessitating the need for compounding to take place under a spectrum of light that will not degrade the drug. Gold fluorescent lighting appears to prevent nifedipine degradation during compounding procedures. Concerning the drug source, the use of commercial nifedipine soft gelatin capsules was problematic, while nifedipine powder USP is a suitable choice for the active pharmaceutical ingredient.

Related Keywords: Susan V. McCluskey, RPh, BS Pharm, Gregory J. Brunn, PharmD, PhD, nifedipine, calcium channel blocker, hypertension, high blood pressure, angina, photodegradation, degradation, light exposure, potency, stability, topical preparations, oral preparations, light sensitivity, vehicle


Printer-Friendly Version

Related Articles from IJPC
Title (Click for Abstract / Details) Author Issue Page View/Buy
Nifedpine in Compounded Oral and Topical Preparations McCluskey Susan V, Brunn Gregory J Mar/Apr 2011 166-169 Buy
Stability of Nitroglyercin 100 mcg/mL Stored in Polypropylene Syringes McCluskey Susan V, Vu Nicole, Rueter John Nov/Dec 2013 515-519 Buy
Nifedipine 1-mg/500-mg Oral Powder Allen Loyd V Jr Sep/Oct 2011 422 Buy
Nifedipine 10-mg/mL Oral Suspension Allen Loyd V Jr Sep/Oct 2011 423 Buy
Current Topical Treatments in Wound Healing - Part 1 Helmke Christopher D Jul/Aug 2004 269 Buy
Nifedipine 4-mg/mL Oral Liquid Allen Loyd V Jr Jul/Aug 2006 303 Buy
Stability of Clopidogrel in Three Extemporaneously Compounded Oral Liquid Preparations Yamreudeewong Weeranuj, Dolence Eric Kurt, Teizeira M Glaucia Sep/Oct 2011 435-437 Buy
Stability of Tranexamic Acid in 0.9% Sodium Chloride, Stored in Type 1 Glass Vials and Ethylene/Propylene Copolymer Plastic Containers McCluskey Susan V, Sztajnkrycer Matthew D, Jenkins Donald A, Zietlow Scott P, Berns Kathleen S, Park Myung S Sep/Oct 2014 432-437 Buy
Novel Approaches to Topical Psoriasis Therapy Koyama Gregory, Liu Jenny, Scaffidi Alyse, Khazraee Maryam, Epstein Benjamin Sep/Oct 2015 357-365 Buy
Effect of Penetration Enhancers on the Percutaneous Delivery of Pain Management Actives Trimble John, Light Bob May/Jun 2016 250-256 Buy